Down-regulation of MicroRNA-133 predicts poor overall survival and regulates the growth and invasive abilities in glioma

Figures & data

Figure 1. Relative expression levels of miR-133 in glioma. *p < .05.

Table 1. The relationship between miR-133 expression and clinicopathological features in glioma patients.

		Median expression of miR-133
Clinicopathologic parameters	Number of cases	Mean ± SD	p Value
Age
<60	13	0.46 ± 0.6102	.175
≥60	17	0.382 ± 0.4560
Sex
Male	14	0.443 ± 0.31	.261
Female	16	0.392 ± 0.181
TNM stage
Stage I + II	12	0.598 ± 0.113	.0318*
Stage III + IV	18	0.295 ± 0.204
Metastasis
No	17	0.618 ± 0.281	.0237*
Yes	13	0.156 ± 0.217

p Values represent the probability from Student’s t-test for miR-133 expression between variable subgroups.

* p < .05.

Figure 2. Effects of miR-133 on cell proliferation and invasion of glioma. (A) The effects of miR-133 mimic on miR-133 expression in U87 cells. The effects of miR-133 mimic on cell proliferation (B) and invasion (C and D) in U87 cells. *p < .05.

Figure 3. FOXC1 is a direct target of miR-133 in glioma. (A) miRNA target soft predicted the target site of miR-133 on the 3’UTR of FOXC1 mRNA. (B) dual-luciferase reporter assay revealed the target role of miR-133 on FOXC1.

Figure 4. FOXC1 was overexpressed in glioma tissue and directly regulated by miR-133. (A) qRT-PCR assay the FOXC1 expression in glioma tissues. *p < .01 versus normal tissues. (B) The effects of miR-133 mimics on the expression levels of FOXC1 mRNA (B) and protein (C). *p < .01 versus control group.